Healthcare [ 5/11 ] | Biotechnology [ 72/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 23 | 0.23 Increased by +235.29% | 0.26 Decreased by -11.54% |
| May 15, 23 | 1.08 Increased by +268.75% | -0.29 Increased by +472.41% |
| Mar 27, 23 | -0.54 Decreased by -74.19% | -0.37 Decreased by -45.95% |
| Nov 14, 22 | -0.31 Decreased by -34.78% | -0.68 Increased by +54.41% |
| Aug 15, 22 | -0.17 Increased by +26.09% | -0.57 Increased by +70.18% |
| May 16, 22 | -0.64 Decreased by -481.82% | -0.41 Decreased by -56.10% |
| Mar 2, 22 | -0.31 Increased by +38.00% | -0.01 Decreased by -3.00 K% |
| Nov 19, 21 | -0.23 Increased by +54.90% | -0.28 Increased by +17.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.09 M Decreased by -220.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -11.58 T Decreased by -126.10 M% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -11.24 M Decreased by -154.20% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -4.99 M Decreased by -52.65% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -2.53 M Increased by +5.20% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -9.18 M Decreased by -510.32% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 360.00 K Increased by +N/A% | -4.42 M Increased by +29.85% | Decreased by -1.23 K% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -3.27 M Increased by +45.25% | Decreased by N/A% Decreased by N/A% |
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.